Figure 13. ROS scavenging and PITX2 silencing improves pulsatile function in hiPSC-CMs. (A) Field potential traces of hiPSC-AMs at 48h. (B, C) Relative trend of beat rate and field potential duration. (D, E) Beat rate and field potential duration of hiPSC-AMs at 48h. * represents P<0.05; ** represents P<0.01; Control: control group; D-galactose: D-galactose-administered group; Edaravone: D-galactose+Edaravone-administered group; si-NC: si-NC transfection+D-galactose administered group; si-PITX2: si-PITX2 transfection+D-galactose-administered group.